Medtronic has announced the Small Annuli Randomized To Evolut or SAPIEN (SMART) head-to-head comparative trial’s two-year ...

Discussions covered identifying eligible patients, increasing the number of specialized centers across Egypt’s governorates, ...

Wednesday, the FDA approved Medtronic plc’s (NYSE:MDT) Evolut FX+ transcatheter aortic valve replacement (TAVR) system for symptomatic severe aortic stenosis. The latest Evolut FX+ TAVR system ...

Medtronic released positive two-year trial Evolut TAVR results that demonstrated superior valve performance in small aortic ...

Medtronic (MDT) released the two-year results of the SMall Annuli Randomized To Evolut or SAPIEN, SMART, Trial, the largest international ...

At the CRT conference 2025, Medtronic presented two-year favorable SMART trial data, which demonstrated the superior performance of the Evolut TAVR valve in patients with AS.

Mandeep Singh Kumar, vice-president and managing director of Medtronic India, emphasised the impact of this collaboration.

Medtronic also recently teamed with Tempus to assess the use of artificial intelligence to identify people eligible for ...

There are several additional anatomic considerations for appropriate case selection in order to minimize post TAVI complications. Importantly, the Medtronic CoreValve device, as well as a ...

(RTTNews) - Medtronic plc (MDT ... international head-to-head comparative trial of transfemoral transcatheter aortic valve replacement (TAVR). In patients with aortic stenosis and a small aortic ...

Medtronic, a leader in medical technology and Philips, a leader in health technology announced the signing of a Memorandum of ...

The collaboration aims to upskill over 300 cardiologists and radiologists in echocardiography and MRI, with a focus on ...